China Biologic Products to Report First Quarter 2014 Financial Results - KWES NewsWest 9 / Midland, Odessa, Big Spring, TX: newswest9.com |

China Biologic Products to Report First Quarter 2014 Financial Results

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE China Biologic Products, Inc.

BEIJING, April 29, 2014 /PRNewwire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter 2014 financial results on Tuesday, May 6, 2014 after the market closes.

The Company's management will hold a conference call at 8:00 a.m. ET on Wednesday, May 7, 2014, which is 8:00 p.m., Beijing Time on May 7, 2014, to discuss first quarter 2014 results. Listeners may access the call by dialing:

US:

1 877 870 4263

International:

1 412 317 0790

Hong Kong:

800 905 945

China:

400 120 1203

Passcode:

10045496

A telephone replay will be available one hour after the conclusion of the conference call through 9:00 a.m., Eastern Time on May 14, 2014. The dial-in details are:

US:

1 877 344 7529

International:

1 412 317 0088

Passcode:

10045496

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Contact: 

China Biologic Products, Inc.

Mr. Ming Yin
Vice President 
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.

Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com

©2012 PR Newswire. All Rights Reserved.